Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Asher Chanan-Khan et al.|Journal of Clinical Oncology|2021Cited by 630
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 studyToby A. Eyre, Peter Hillmen, Anna Schuh et al.|The Lancet Haematology|2021Cited by 60